PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. - Lu C; Yan HH; Zhang CY; Chen SY; Li YS; Wang BC; Xu CR; Tu HY; Zhong WZ; Zhou Q; Zhang XC; Wu YL; et al. (Clinical lung cancer, 2025)